LivaNova PLC
$ 68.35
-0.10%
23 Feb - close price
- Market Cap 3,736,110,000 USD
- Current Price $ 68.35
- High / Low $ 68.38 / 66.43
- Stock P/E N/A
- Book Value 21.19
- EPS -3.98
- Next Earning Report 2026-02-25
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE -0.18 %
- 52 Week High 69.31
- 52 Week Low 32.48
About
LivaNova PLC, a medical device company, designs, develops, manufactures and sells therapeutic solutions globally. The company is headquartered in London, the United Kingdom.
Analyst Target Price
$73.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-07-29 | 2025-04-29 | 2025-02-19 | 2024-10-30 | 2024-07-31 | 2024-05-01 | 2024-02-21 | 2023-11-01 | 2023-07-26 | 2023-05-03 | 2023-02-22 |
| Reported EPS | 1.11 | 1.05 | 0.88 | 0.81 | 0.9 | 0.93 | 0.73 | 0.87 | 0.73 | 0.78 | 0.43 | 0.81 |
| Estimated EPS | 0.92 | 0.868 | 0.49 | 0.8006 | 0.72 | 0.78 | 0.49 | 0.77 | 0.64 | 0.54 | 0.39 | 0.73 |
| Surprise | 0.19 | 0.182 | 0.39 | 0.0094 | 0.18 | 0.15 | 0.24 | 0.1 | 0.09 | 0.24 | 0.04 | 0.08 |
| Surprise Percentage | 20.6522% | 20.9677% | 79.5918% | 1.1741% | 25% | 19.2308% | 48.9796% | 12.987% | 14.0625% | 44.4444% | 10.2564% | 10.9589% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-25 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.67 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LIVN
2026-02-21 12:14:37
Medical device company LivaNova is facing multiple class action lawsuits following an October 2023 cyberattack that exposed protected health information for 180,000 patients. The lawsuits allege negligence and failure to implement adequate cybersecurity measures, as well as delayed breach notifications, which were sent six months after detection. Plaintiffs are seeking damages and injunctive relief to ensure improved security practices by LivaNova.
2026-02-19 14:58:14
LivaNova PLC (LIVN) stock reached a new 52-week high of $68.00, representing a significant increase of nearly 110% from its 52-week low. Despite not being profitable in the past twelve months, analysts predict net income growth this year and profitability by 2026, driven by strategic initiatives, product developments, and favorable regulatory decisions like increased Medicare reimbursement rates for its VNS Therapy. The company's financial health is rated "GREAT" by InvestingPro, and it operates with moderate debt, making it appear slightly undervalued.
2026-02-19 14:58:13
Piper Sandler has reiterated an Overweight rating and an $85.00 price target for Livanova (NASDAQ:LIVN), citing an expected upside in fiscal year 2026. The firm anticipates the company will guide to 5-7% revenue growth and adjusted earnings per share of $4.10 to $4.25 for FY26, alongside potential benefits from recent reimbursement changes for its epilepsy franchise. This positive outlook is supported by a strong gross profit margin and solid cash generation, with Piper Sandler identifying Livanova as a favored small- to mid-cap value name.
2026-02-19 11:28:18
LivaNova PLC stock reached a 52-week high of $68.00, marking a significant increase of almost 110% from its 52-week low. Analysts anticipate future profitability for the medical technology company in 2026, with an upcoming earnings report on February 25 potentially serving as a further catalyst for price movement. Recent positive developments include new analyst ratings, a key commercialization appointment, and increased Medicare reimbursement rates for its VNS Therapy.
2026-02-18 16:27:59
LivaNova PLC stock has reached a new 52-week high of $68.00, representing a nearly 110% increase from its 52-week low. The company has seen a 41.83% rise in its stock price over the past year, with a 25.7% gain in the last six months, driven by strong investor confidence and strategic developments. Analysts anticipate profitability in 2026, and the company is considered slightly undervalued with a "GREAT" financial health score, ahead of its earnings report on February 25.
2026-02-18 15:28:18
LivaNova (LIVN) is scheduled to release its Q4 2025 earnings before market open on Wednesday, February 25, 2026. Analysts project earnings of $0.80 per share and revenue of approximately $354.3 million for the quarter. The company currently holds a "Moderate Buy" consensus rating from analysts, with a target price of $69.38.
